Excitingly, several recent studies in preclinical animal models have suggested that targeting RET function could both limit tumor growth and resensitize tumors to endocrine therapies, prolonging the efficacy of these agents (Nguyen et al., 2015; Andreucci et al., 2016; Hatem et al., 2016; Gattelli et al., 2018). Here, RET is linked to neoplasm.